Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma
Overview of attention for article published in Blood, November 2020
Altmetric Attention Score: 6
About this Attention Score
-
Good Attention Score compared to outputs of the same age (71st percentile)
-
Above-average Attention Score compared to outputs of the same age and source (60th percentile)
Readers on
- mendeley
- 6 Mendeley